Goldman Sachs analyst Salveen Richter initiates coverage on Seaport Therapeutics (NASDAQ: SPTX) with a Early-Stage Biotech rating.The analyst comments: “We ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage